Timing of pulmonary valve replacement in patients with corrected Fallot to prevent QRS prolongation by Romeo, J.L.R. (Jamie) et al.
Cite this article as: Romeo JLR, Takkenberg JJM, Cuypers JAAE, de Groot NMS, van de Woestijne P, Bruining N et al. Timing of pulmonary valve replacement in
patients with corrected Fallot to prevent QRS prolongation. Eur J Cardiothorac Surg 2020;58:559–66.
Timing of pulmonary valve replacement in patients with
corrected Fallot to prevent QRS prolongation
Jamie L.R. Romeoa, Johanna J.M. Takkenberg a, Judith A.A.E. Cuypers b, Natasha M.S. de Grootc,
Pieter van deWoestijnea, Nico Bruining d, Ad J.J.C. Bogers a andM. Mostafa Mokhlesa,*
a Department of Cardiothoracic Surgery, Erasmus University Medical Center, Rotterdam, Netherlands
b Department of Congenital Cardiology, Erasmus University Medical Center, Rotterdam, Netherlands
c Department of Cardiology, Erasmus University Medical Center, Rotterdam, Netherlands
d Department of Clinical and Experimental Information Procession, Erasmus University Medical Center, Rotterdam, Netherlands
* Corresponding author. Department of Cardiothoracic Surgery, Erasmus University Medical Center, Doctor Molewaterplein 40, 3015 GD Rotterdam, Netherlands.
Tel: +31-10-7030771; fax: +31-10-7033993; e-mail: m.mokhles@erasmusmc.nl (M.M. Mokhles).
Received 5 November 2019; received in revised form 11 January 2020; accepted 23 January 2020
Abstract
OBJECTIVES: Timing of pulmonary valve replacement (PVR) remains one of the most heavily debated topics in congenital cardiac surgery.
We aimed to analyse the temporal evolution of QRS duration before and after PVR.
METHODS: We included 158 consecutive patients who underwent PVR after previous correction with transannular patch. All 3549 avail-
able serial standard 12-lead surface QRS measurements of 158 (100%) patients were analysed with linear mixed-effect modelling.
RESULTS: PVR was performed at a mean age of 28.0 ± 10.7 years, 23.4 ± 8.4 years after correction. Hospital survival was 98.1%. A longer
time interval between ToF correction and PVR (P < 0.001), and an older age at correction (P = 0.015) were predictive of progressive QRS
prolongation after PVR. Women on average had a shorter QRS duration (P = 0.005) after PVR. The model predicted that in patients cor-
rected early (model age 0.5 years), PVR within 17 years after correction leads to narrowing or stabilization of QRS width. PVR beyond
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17 years was associated with prolongation of QRS duration. In a patient corrected late (model age 5 years), PVR has to be performed within
15 years after correction to prevent prolongation. Finally, a longer time period between correction and PVR was associated with an
increased hazard of cardiac death (hazard ratio 1.097, 95% confidence interval 1.002–1.200).
CONCLUSIONS: Prolongation of QRS duration after PVR was associated with a longer time between correction and PVR, older age at cor-
rection and male sex. Prevention of progressive QRS prolongation by earlier PVR can potentially reduce the hazard of adverse events after
PVR.
Keywords: Tetralogy of Fallot • QRS • Pulmonary valve replacement • Allograft • Timing
ABBREVIATIONS
CI Confidence interval
HR Hazard ratio
PR Pulmonary regurgitation
PVR Pulmonary valve replacement
RV Right ventricular
TOF Tetralogy of Fallot
INTRODUCTION
Tetralogy of Fallot (TOF) is the most common cyanotic congenital
heart disease in life births and can be repaired safely at a young
age [1]. However, long-term survival and freedom from reinter-
vention are limited by the presence of ventricular arrhythmia,
sudden death and heart failure [2, 3]. Ventricular tachyarrhythmia
in repaired TOF patients is presumed to be the primary cause of
sudden death. In the current paradigm, it is believed that chronic
volume overload, caused by residual pulmonary regurgitation
(PR), leads to right ventricular (RV) dilatation. This ultimately pre-
disposes for electromechanical dissociation and heart failure
[3–5]. Pulmonary valve replacement (PVR) treats PR and results in
RV remodelling during the first postoperative years [6]. However,
RV reverse remodelling does not occur in every patient and ad-
verse events still occur frequently after PVR [7]. It is currently un-
known how to define and determine the optimal time frame
within which PVR should be performed.
QRS duration assessed through standardized 12-lead electro-
cardiogram may potentially be a prognostic electrocardiographic
biomarker for adverse cardiac events. A QRS duration exceeding
170–180 ms has repeatedly been indicated as independent pre-
dictor for malignant ventricular arrhythmia and sudden cardiac
death [3, 8]. Furthermore, prolonged QRS duration is associated
with regional wall motion abnormalities, RV dilatation [5],
increased biventricular wall mass [9] and decreased left ventricu-
lar ejection fraction [9]. QRS duration can, therefore, be a poten-
tially meaningful surrogate marker reflecting the impact of
chronic severe PR and RV dilatation. A better understanding of
the temporal evolution of QRS duration in patients with cor-
rected TOF before and after PVR could improve timing of PVR.
We determined the temporal evolution of QRS duration before
and after PVR in a consecutive cohort of corrected TOF patients.
METHODS
All consecutive patients (N = 158) who underwent surgical PVR in
the Erasmus University Medical Center Rotterdam between
August 1987 and November 2017 after complete correction of
ToF with a transannular patch were included retrospectively.
Gore-Tex transannular patches were used without monocusp re-
construction. Patients with pulmonary atresia, ventricular septal
defects and systemic collateral arteries were excluded. The insti-
tutional review board approved this study and waived individual
informed consent (MEC 12-477).
Indication and surgical technique
All patients were discussed in structured multidisciplinary meet-
ings (congenital heart team meeting) including congenital cardi-
ologists, congenital cardiac surgeons and radiologist, prior to
interventions. All indications for PVR were severe PR with signs of
progressive RV dilatation or reduced function with or without
cardiac-related symptoms. PVR was generally performed through
median sternotomy, using standard cardiopulmonary bypass as
previously described. In our centre, cryopreserved homografts
have been and still are exclusively used for RV outflow tract re-
construction, given their excellent results in terms of structural
valve deterioration, and low rates of endocarditis and valve
thrombosis [10].
Study design
After discharge, patients were followed though our outpatient
clinic at 1 week, 6 weeks, 6 months and annually thereafter.
Standardized 12 lead (25 mm/s, 10 mm/mV) surface electrocar-
diograms (ECGs) were acquired during every visit to our out-
patient clinic regardless of symptomatology. Valve-related events
and mortality were reported according to the guidelines for
reporting valve-related mortality and morbidity [11]. Follow-up
within 2 years of study closing (February 2018) was available for
151 (97.4%) patients discharged alive after PVR. Four patients
were lost to follow-up after PVR due to emigration (n = 3) and
unknown reasons (n = 1). QRS duration as marker of ventricular
depolarization was extracted from computerized calculations
based on the VERITASTM ECG algorithm (Mortara Instrument,
2018, Milwaukee, WI, USA). Paced rhythms were excluded from
the analysis and ECGs were censored in case of re-PVR. Sixteen
(10.1%) patients underwent pacemaker implantation
22.0 ± 10.8 years after correction of which 4 before PVR, 10 after
PVR and 2 concomitantly to PVR. An integrated assessment of
the severity and physiology of PR was based on a multi-window
perspective using transthoracic colour flow and pulsed-wave
Doppler echocardiography and qualitatively graded from none,
light, moderate and severe. Significant regurgitation was defined
as moderate or severe regurgitation [12].
Statistical analysis
Continuous outcomes are reported as means ± standard devia-
tions or medians with range, as appropriate. Continuous variables
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between groups were compared using independent samples t-
tests, one-way analysis of variance (ANOVA) analysis, or Kruskal–
Wallis tests, as appropriate. Frequencies were presented with per-
centages and compared using v2 tests. Correlations between con-
tinuous baseline variables were calculated using Pearson
correlation, and reported with 2-tailed significance levels. Time-
dependent outcomes were analysed using life tables and visual-
ized with Kaplan–Meier plots as a function of time to or since
PVR. Sex, age at correction, time interval between correction and
PVR, age at PVR, length at PVR, weight at PVR, creatinine (mmol/
l) at PVR and QRS duration at PVR were studied as potential risk
factors by univariate and multivariate Cox proportional hazards
models, using a backward stepwise elimination process with a
threshold of (P > 0.05) (Table 1). Missing values were considered
missing at random and not imputed due to the very small
amount of missing values. Analyses were exploratory in nature
and no adjustment for multiple testing was performed.
Continuous repeated measurements of QRS duration were
analysed using linear mixed-effects modelling [13]. A random
effects structure with time was used to account for correlations
between repeated measurements in the same patient and irregu-
larly timed measurements. QRS duration was modelled as a func-
tion of time to PVR, including fixed effects for sex and age at
correction. Time in relation to PVR was entered as a natural cubic
spline with 2 internal knots. Furthermore, potential interaction
effects between age at correction, sex and time between correc-
tion and PVR, were explored. Effect plots were provided to illus-
trate the temporal evolution of QRS duration of an average
patient. Given a significant trend towards earlier repair in our
practice as well as contemporary surgical practice, early and late
repair were defined as correction at the age of 6 months and
5 years, respectively.
Statistical analyses were performed with SPSS (IBM Corp.
Released 2016. IBM SPSS Statistics for Windows, Version 24.0.
Armonk, NY: IBM Corp.) and R (LME4 package) [R Core Team
(2016)].
RESULTS
Baseline patients and surgical characteristics
A total of 158 consecutive patients underwent surgical PVR after
previous ToF correction with a transannular patch. Median age at
correction was 2.0 years (range 5 days–29.5 years) and 90 (57%)
were males (Table 2). Mean time between correction and PVR
was 23.4 ± 8.2 years (range 1.93–44.) at a mean age of
28.0 ± 10.7 years (range 2.1–66.4). Moderate or severe regurgita-
tion were present in 155 (98.1%) patients before PVR.
Supplementary Material, Fig. S1A–C shows the trend during the
study period of age at ToF correction, at PVR and the time be-
tween correction and PVR. The figures indicate an increasingly
younger age at correction and a relatively stable time interval be-
tween correction and subsequent PVR.
Clinical outcome
Hospital survival was 98.1% (n = 155). Three patients (1.9%) died
shortly after PVR of sudden cardiac death presumably due to ar-
rhythmia (n = 1), severe oesophageal bleeding and pulmonary in-
fection after concomitant tracheal resection (n = 1) and repeated
rhythm disturbances with severe biventricular heart failure (n = 1).
All 3 patients had severe PR with RV dilatation and symptoms.
Mean follow-up time after PVR was 10.0 ± 7.0 years (median 9.3,
range 0.3–28.7 years, total 1555 patient years), during which 18
patients underwent a second PVR (6 surgically, 12 percutaneous-
ly), after a mean period of 7.9 ± 5.5 years. Freedom from re-PVR
after 10 and 15 years was 84 ± 4% and 81 ± 5%, respectively.
Late cardiac death was observed in 9 patients, of whom 3
(33%) were also classified as having an extremely prolonged QRS
duration (>230 ms) post-PVR (Table 3). The relative risk of cardiac
death in patients with an extremely prolonged QRS duration was
7.25 [95% confidence interval (CI) 2.48–8.74; P = 0.002]. The 9
patients who died of cardiac causes were corrected at an average
age of 12.4 ± 5.4 years (median 12.7, 4.5–23.0) and underwent
PVR 28.6 ± 5.6 years later (median 29.2, range 18.4–36.8). They
died 11.0 ± 4.2 years after PVR, at an average age of
52.0 ± 8.9 years. Cumulative freedom from cardiac death of all
hospital survivors after 10 and 15 years post-PVR was 90 ± 4%
and 83 ± 6%, respectively (Fig. 1).
QRS duration over time
In all but 1 patient, ECGs were available (Table 2). One patient
underwent correction in 1976 and subsequent PVR in 1991 after
which he died 14 days later due to severe rhythm disturbances.
No ECGs could be retrieved from this patient.
Table 1: Cox proportional hazards model for cardiac death
Variables Univariable Multivariable
HR P-value HRa P-value
Cardiac death
Sex 0.204 (0.042–0.989) 0.048 0.130 (0.016–1.085) 0.058
Age at correction 1.111 (1.030–1.198) 0.006
Time correction-PVRb 1.119 (1.034–1.211) 0.005 1.097 (1.002–1.200) 0.005
Age at PVR 1.095 (1.043–1.150) <0.001
Length at PVR 1.058 (0.996–1.123) 0.069
Weight at PVR 1.053 (1.009–1.098) 0.017
Creatinine (mmol/l) 1.032 (0.988–1.079) 0.160
QRS-duration pre PVR 1.004 (0.981–1.027) 0.733
aBecause of the correlations between the covariates and linear dependency between age at correction, time-between correction and PVR, age at PVR, length and
weight at PVR, only 1 (i.e. time between correction and PVR) was entered in the multivariable part of the analysis.
HR: hazard ratio; PVR: pulmonary valve replacement.
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Patients are presented in different groups based on the time
interval between ToF correction and PVR (interval between ToF
correction and PVR <10 vs 10–20 vs 20–30 vs >30 years)
(Table 2). The QRS duration prior to PVR was not associated
with the time interval between correction and PVR (r = 0.089,
P = 0.311), and was comparable among the 4 groups (P = 0.674).
However, the time interval between correction and PVR showed
significant correlations with other baseline factors. A longer time
interval between correction and PVR was correlated with older
age at correction (r = 0.189, P = 0.017), older age at PVR
(r = 0.864, P < 0.001), higher creatinine (r = 0.487, P < 0.001),
greater diameter of allograft (r = 0.207, P = 0.009), greater height
at PVR (r = 0.443, P < 0.001) and higher weight at PVR (r = 0.603,
P < 0.001).
Figure 2A and B provides a panel of effect plots of QRS dur-
ation over time before and after PVR. Temporal trends are
depicted for male and female patients corrected early (Fig. 1A)
and late (Fig. 1B). Different time intervals between correction and
PVR are vertically depicted (10, 20, 30 and 40 years after correc-
tion, respectively). Our online application (https://cts-erasmusmc.
shinyapps.io/fallotqrs/) provides results for any combination of
choice. The figure illustrates that no major changes occur in QRS
duration before PVR, and QRS duration is comparable right be-
fore PVR, regardless of duration since correction. However, im-
portant changes in the overall slope of the evolution of QRS
duration can be observed in patients who undergo PVR beyond
a certain period. After PVR, a longer time period between correc-
tion and PVR (P < 0.001), and an older age at correction
Table 2: Baseline, surgical and diagnostic characteristics
Overall Interval
<10 years
Interval
10–20 years
Interval
20–30 years
Interval
>30 years
P-valuea
Patients, n (%) 158 (100) 11 (7.0) 42 (26.6) 73 (46.2) 32 (20.3)
Male gender, n (%) 90 (57.0) 7 (63.6) 19 (45.2) 41 (56.2) 23 (71.9) 0.140
Shunt before correction, n (%) 43 (27.2) 3 (27.3) 15 (35.7) 15 (20.5) 10 (31.3) 0.330
Age at correction (years), mean ± SD 4.6 ± 5.5 3.1 ± 5.5 4.9 ± 7.0 3.7 ± 3.8 6.9 ± 6.0 0.035
Time correction-PVR (years), mean ± SD 23.4 ± 8.2 6.7 ± 2.3 16.3 ± 2.9 25.0 ± 2.8 34.5 ± 3.3 <0.001
Age at PVR (years), mean ± SD 28.0 ± 10.7 9.8 ± 5.9 21.1 ± 7.2 28.8 ± 5.7 41.5 ± 7.8 <0.001
Haemodynamic indication, n (%)
Severe regurgitation 137 (86.7) 7 (63.6) 38 (90.5) 64 (87.7) 28 (87.5) 0.264
Severe stenosis 3 (1.9) 1 (9.1) 1 (2.4) 1 (1.4) 0 (0)
Mixed 18 (11.4) 3 (27.3 3 (7.1) 8 (11.) 4 (12.5)
RVOT peak gradient (mmHg) (n = 145), mean ± SD 18.1 ± 20.7 46.1 ± 53.3 20.0 ± 17.5 14.9 ± 13.7 13.7 ± 11.0 <0.001
BSAb (n = 139) mean ± SD 1.78 ± 0.27 1.15 ± 0.35 1.61 ± 0.21 1.84 ± 0.20 1.94 ± 0.17 <0.001
Previous heart operationsC (%), n (%)
1 101 (63.9) 7 (63.6) 24 (57.1) 48 (65.8) 22 (68.8) 0.640
2 46 (29.1) 3 (27.3) 13 (31.0) 22 (30.1) 8 (25.0)
3 9 (5.9) 1 (9.1) 3 (7.1) 3 (4.1) 2 (6.3)
4 2 (1.3) 0 (0) 2 (4.8) 0 (0) 0 (0)
Pre-PVR QRS durationd (n = 132), mean ± SD 150 ± 31 141 ± 32 147 ± 31 150 ± 30 155 ± 35 0.674
Elective (>24 h), n (%) 147 (93.0) 10 (90.9) 38 (90.5) 69 (94.5) 30 (93.8) 0.855
Diuretic use (n = 156), n (%) 15 (9.6) 1 (9.1) 4 (9.8) 8 (11.1) 2 (6.3) 0.895
Sinus rhythm (n = 156), n (%) 137 (87.8) 11 (100) 38 (92.7) 63 (87.5) 25 (78.1) 0.154
Creatinine (mmol/l) (n = 153), mean ± SD 70 ± 19 43 ± 16 63 ± 17 74 ± 14 79 ± 20 <0.001
Cross-clamp time (n = 141), mean ± SD 22 ± 43 47 ± 34 29 ± 42 17 ± 41 31 ± 48 0.101
Perfusion time (n = 147), mean ± SD 111 ± 63 106 ± 50 125 ± 62 101 ± 66 115 ± 58 0.296
Pulmonary allografte (n = 154), n (%) 154 (97.5) 11 (100) 40 (95.2) 72 (98.6) 31 (96.9) 0.665
Diameter of allograft (mm) (n = 157), median (range) 24 (15–28) 22 (15–25) 24 (21–28) 24 (21–28) 24 (21–28) 0.440
Hospital mortality, n (%) 3 (1.9) 0 (0) 1 (2.4) 1 (1.4) 1 (3.1) 0.889
ECG
Total number available, n 3549 137 809 1816 787
Pre-PVR (%), n (%) 323 (9.1) 11 (8.0) 49 (6.1) 185 (10.2) 78 (9.9) 0.242
Unique patients, n (%) 157 (99.4) 11 (100) 41 (97.6) 73 (100) 32 (100)
ECGs/patient, n 22.5 12.5 19.7 24.9 24.6 0.142
Echocardiography
Total number available, n 1747 130 472 821 324
Pre-PVR (%), n (%) 533 (30.5) 29 (22.3) 85 (18.0) 282 (34.3) 137 (42.3) 0.151
Unique patients, n (%) 156 (98.7) 11 (100) 41 (97.6) 73 (100) 31 (96.9)
Echos/patient, n 11.1 11.8 11.5 11.2 10.1 0.242
Follow-up duration (years), mean ± SD 9.6 ± 9.6 12.3 ± 10.8 12.3 ± 8.0 9.3 ± 5.3 7.3 ± 6.2 0.010
Max post-PVR QRS duration, mean ± SD 158 ± 37 142 ± 35 153 ± 34 159 ± 32 168 ± 48 NA
aContinuous variables between groups are compared using one-way ANOVA analysis or Kruskal–Wallis tests.
bAccording to the formula of Mosteller.
CAll previous open heart surgeries, including complete correction.
dQRS duration nearest in time but within 1 year prior to PVR.
ePulmonary allograft or aortic allograft.
BSA: body surface area; NA: not applicable; PR: pulmonary regurgitation; PVR: pulmonary valve replacement; RVOT: right ventricular outflow tract; SD: standard
deviation.
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(P = 0.0185) were both significantly and independently associated
with progression of QRS duration.
Pacemaker and ICD
Among hospital survivors without a pacemaker, the time interval
between correction and PVR was not associated with the hazard
of late pacemaker implantation [hazard ratio (HR) 1.035, 95% CI
0.958–1.118; P = 0.383]. A longer time interval between correction
and PVR was, however, associated with an increased hazard of
late implantation of an implantable cardioverter-defibrillator
(ICD) (HR 1.137, 95% CI 1.039–1.244; P = 0.005).
DISCUSSION
This study is the first to show an association between timing of
PVR and QRS duration using innovative and advanced
statistics to model the individual long-term evolution of QRS
duration before and after PVR in a homogenous group of cor-
rected ToF patients. QRS duration after PVR is significantly
associated with a longer time interval between initial correc-
tion and PVR, a higher age at correction and sex. In patients
who undergo early ToF correction, progressive QRS prolonga-
tion after PVR can be prevented by intervening within
17 years after correction. In patients with ToF correction at a
later age, progressive QRS prolongation after PVR can be pre-
vented by intervening within 15 years after correction. The
time interval between ToF correction and PVR is therefore
associated with postoperative QRS duration, cardiac death
and the hazard of postoperative ICD implantation. QRS dur-
ation is an important risk factor before and after PVR in cor-
rected ToF patients, and prevention of prolongation might
improve the outcome of these patients.
PVR and QRS duration
Few published studies have investigated the relation between
PVR and QRS duration [14–29]. However, the results are hetero-
geneous with some authors reporting a stable QRS duration
[17, 19, 20, 22, 28], some an increase [16] and some a decrease
[6, 15, 18, 21, 25, 27] after PVR in corrected ToF patients.
Therrien et al. [28] were the first to report a stabilization in QRS
duration after PVR in corrected ToF patients compared to a con-
trol group who had not undergone PVR. van Huysduynen et al.
[29] were the first to report a decline in QRS duration following
PVR in 26 patients with corrected ToF with at least moderate re-
gurgitation. Oosterhof et al. studied 99 corrected TOF patients
who underwent a first PVR and reported an initial decline in
mean QRS duration directly post-surgery. QRS duration
increased, however, during a median follow-up of 5 years in
patients with preoperative QRS >120 ms. In patients with a pre-
operative QRS <120 ms, no increase was reported [30]. The mixed
results of QRS duration could potentially also be explained by
undisclosed differences in time interval between correction and
Table 3: Characteristics of patients with extreme QRS (>230) and/or late cardiac death
Gender Age at
correction
Age at
PVR
Time
correction-PVR
Age at last
follow-up/death
Late cardiac
death
Extreme
QRS
PM Max
QRS
PM Max QRS
before PM
Male 9.3 40.7 31.4 48.8 Heart failure Yes After PVR 336 After PVR 206
Male 13.4 48.4 35.0 64.3 Heart failure Yes Never 260 Never 260
Male 13.0 42.2 29.2 53.2 SUUD Yes Never 260 Never 260
Female 11.8 41.0 29.2 56.7 SUUD No Never 174 Never 174
Male 16.5 43.7 27.2 53.3 Heart failure No Never 142 Never 142
Female 12.7 38.8 26.1 51.6 Heart failure No Never 222 Never 222
Male 7.0 43.8 36.8 54.7 Heart failure No Never 194 Never 194
Male 4.5 28.9 24.3 31.2 SUUD No Never 178 Never 178
Male 23.0 41.4 18.4 54.3 Heart failure No Never 186 Never 186
Male 4.4 44.4 40.0 47.8 Alive Yes Never 250 Never 250
Male 8.4 41.7 33.2 60.8 Alive Yes Never 252 Never 252
Female 2.0 24.5 22.4 43.4 Alive Yes At PVR 299 At PVR NA
Male 8.8 37.8 29.0 50.6 Alive Yes After correction 292 After correction NA
Female 0.2 23.4 23.2 39.1 Alive Yes After PVR 226 After PVR 226
Male 10.5 43.8 33.2 56.4 Alive Yes After PVR 239 After PVR 234
Male 2.3 32.4 30.2 41.5 Alive Yes After PVR 233 After PVR 176
NA: not applicable; PM: pacemaker; PVR: pulmonary valve replacement; SUUD: sudden unexplained unexpected death.
Figure 1: Kaplan–Meier curve depicting cumulative freedom from cardiac
death after PVR (solid line) along with 95% confidence intervals (dotted lines).
PVR: pulmonary valve replacement.
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Figure 2: Panel figure of the longitudinal QRS (in ms) evolution for 2 fictional patients of both genders. Age at correction of 6 months (A) and 5 years (B) were chosen.
Time between correction and PVR increases from 10 to 40 years (vertically). Thus, the figure indicates the longitudinal evolution of QRS duration for a child corrected
at 6 months (A) and 5 years (B), for both males and females, given 4 different moments of PVR after correction (vertically depicted; 10, 20, 30 and 40 years, respective-
ly). Post-PVR evolution of QRS duration shows a progressive prolongation in patients who underwent PVR 30 and 40 years after correction, despite comparable QRS
durations right before PVR. PVR: pulmonary valve replacement.
564 J.L.R. Romeo et al. / European Journal of Cardio-Thoracic Surgery
D
ow
nloaded from
 https://academ
ic.oup.com
/ejcts/article/58/3/559/5810148 by Erasm
us U
niversiteit R
otterdam
 user on 09 Septem
ber 2020
PVR. Mixed-effect modelling enabled us to model the variability
that is inherent to and only observable in a longitudinal design
that considers irregularly scheduled and collected measurements
and accepts a non-linear evolution.
QRS prolongation as risk factor
Prolongation of QRS duration has been reported despite suc-
cessful PVR and is predictive of adverse outcome [16, 25, 29].
As multiple studies have demonstrated the malignant nature of
QRS progression as a substrate for cardiac dysfunction and
increasing depolarization disturbances, preventing this postop-
erative prolongation seems imperative [25, 29]. Scherptong
et al. [25] reported that a post PVR QRS duration exceeding
180 ms was associated with a reduced freedom from a com-
posite end point including death, re-PVR, ventricular tachyar-
rhythmia and symptomatic heart failure after 5 years.
Stabilization of QRS duration after PVR has occasionally been
associated with a reduced frequency of ventricular tachycardia
[18]. Harrild et al. studied 98 corrected ToF patients who under-
went PVR 20 years after correction at a mean age of 5 years. In
a later study, QRS duration did not change after PVR, and
matched controls with significant PR and RV dilatation who did
not undergo PVR showed no differences in reported ventricular
tachycardia or death [17]. The average delay to PVR of
19.7 years is close to the time frame proposed by this study
with regard to prolongation prevention. Similarly, the change
rate of QRS prolongation and older age at correction have
been associated with an increased incidence of ventricular
tachyarrhythmia and sudden death [5]. These findings underline
the clinical importance of QRS duration after PVR and the rele-
vance of preventing progression.
It could be hypothesized that QRS duration is a reflection of
RV remodelling, often shown by progressive RV end-diastolic
volume [4, 5]. The relevance of preventing progressive QRS dur-
ation could be similar in that regard as well, aimed at preserving
or even improving ventricular function, given that the correlation
between QRS duration and RV end-diastolic volume persists after
PVR. QRS duration could, therefore, act both as a biomarker for
volumetric and functional change, as well as a risk factor for late
adverse events. Unfortunately, no serial volumetric data, prefer-
ably by magnetic resonance imaging, were available of sufficient
patients to conduct a similar analysis. The design of the current
study can, however, be adapted with RV volume over time to po-
tentially identify the pivot point to prevent further RV dilatation,
heart failure and malignant arrhythmia.
CONCLUSION
The decision whether to intervene in corrected ToF patients
should ideally depend on the combination of multiple bio-
markers with the clinical state of the patient. QRS duration is an
easily obtainable electrocardiographic biomarker with extensive
prognostic capabilities in ToF patients suffering from chronic PR
who undergo PVR.
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